BIO5 member Deepta Bhattacharya and a team of University of Arizona Health Sciences researchers found that initial COVID-19 vaccines did not hinder the immune system’s ability to respond to new variants.

BIO5 member Bruce Tabashnik and fellow researchers at the University of Arizona have uncovered how nature helps delay insect resistance to genetically engineered crops.

Hanami Inagaki, a 2025 University of Arizona alumna, reflects on how the BIO5 Ambassadors program helped her grow as a science communicator, leader, and aspiring researcher in green chemistry.

BIO5 members Dongkyun Kang and Clara Curiel-Lewandrowski are part of a team that hope to image nerve endings and create objective, quantitative biomarkers for chemotherapy-induced peripheral neuropathy, or CIPN, a common and painful side effect of chemotherapy drugs.

Branch Therapeutics, a University of Arizona startup co-founded by BIO5 members Christopher Hulme and Curtis Thorne, has received $4 million in seed funding to advance its development of targeted therapies for cancer and other diseases.

BIO5 member Mohammed Hassan is leading groundbreaking work on the development of the world's first phototransistor capable of operating at petahertz speeds under ambient conditions. Petahertz refers to a frequency of one million billion cycles per second, representing a significant leap in speed and performance.

BIO5 member Philipp Gutruf and his team at the University of Arizona have developed a new class of wearable devices designed to monitor health for longer periods without recharging.

BIO5 member Jeff Burgess and University of Arizona Health Sciences researchers found that health care workers and firefighters have higher levels of PFAS in their blood than the general population.

Biochemistry major Gavin Arnold is taking advantage of undergraduate University of Arizona research opportunities by conducting research with BIO5 member Ying-Hui Chou on using brain stimulation treatment to improve patients' cognitive abilities.